SCHEMBL2301965

SCHEMBL2301965

Cc1ccc(NS(=O)(=O)c2ccc(N3CCNC3=O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
MAPT P10636 5/20 0.60
RECQL P46063 1/20 0.60
USP2 O75604 1/20 0.59
HSD17B10 Q99714 1/20 0.54
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
CA12 O43570 1/20 0.50
PKM P14618 1/20 0.49
KMT2A Q03164 4/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
MEN1 O00255 3/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
GFER P55789 1/20 0.49
MCL1 Q07820 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301942 0.88 MAPT (0.54) ALDH1A1MAPTRECQLUSP2PKM
SCHEMBL2300518 0.88 MAPT (0.61) ALDH1A1MAPTCA1CA2PKM
SCHEMBL14239653 0.87 MAPT (0.47) ALDH1A1MAPTRECQLUSP2PKM
SCHEMBL2302229 0.87 HTR6 (0.47) ALDH1A1MAPTRECQLUSP2PKM
SCHEMBL2301221 0.87 IDO1 (0.50) ALDH1A1MAPTRECQLPKMKMT2A
SCHEMBL2305062 0.87 CES1 (0.58) ALDH1A1MAPTCA1CA2KMT2A
SCHEMBL2299887 0.86 HTR6 (0.56) ALDH1A1MAPTHSD17B10CA1CA2
SCHEMBL2301155 0.86 KMT2A (0.61) ALDH1A1MAPTCA1CA2CA9
SCHEMBL2303169 0.86 ALDH1A1 (0.58) ALDH1A1MAPTCA1CA2KMT2A
SCHEMBL2357330 0.86 ALDH1A1 (0.61) ALDH1A1MAPTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 ALDH1A1 1937/4885MAPT 4618/4885RECQL 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.